Evidence map›Paper›PMID 21483783›Full record

ArticlePloS one2011

Inhibition of reactive gliosis attenuates excitotoxicity-mediated death of retinal ganglion cells.

Bhagyalaxmi S Ganesh, Shravan K Chintala

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 81 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Anti-Inflammatory Effects of GLP-1R Activation in the Retina.International journal of molecular sciences · 2022
    Review
  8. The innate immune system in diabetic retinopathy.Progress in retinal and eye research · 2021
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Bhagyalaxmi S GaneshEye Research Institute of Oakland University, Rochester, Minnesota, United States of America.
Shravan K Chintala
Oakland University · USSmith-Kettlewell Eye Research Institute · US

Funding

Vision Research Infrastructure Development Grant (R24)R24EY014803 · NEI · OAKLAND UNIVERSITY · PI GIBLIN, FRANK JOSEPH · 2003 to 2007
$1.1M
Proteases in IOP-mediated glaucomatous damageR01EY017853 · NEI · OAKLAND UNIVERSITY · PI CHINTALA, SHRAVAN K · 2009 to 2010
$740k
NEI NIH HHS EY014803NEI NIH HHS R01 EY017853NEI NIH HHS R24 EY014803
6 · The paper itself

Abstract

Reactive gliosis is a hallmark of many retinal neurodegenerative conditions, including glaucoma. Although a majority of studies to date have concentrated on reactive gliosis in the optic nerve head, very few studies have been initiated to investigate the role of reactive gliosis in the retina. We have previously shown that reactive glial cells synthesize elevated levels of proteases, and these proteases, in turn, promote the death of retinal ganglion cells (RGCs). In this investigation, we have used two glial toxins to inhibit reactive gliosis and have evaluated their effect on protease-mediated death of RGCs. Kainic acid was injected into the vitreous humor of C57BL/6 mice to induce reactive gliosis and death of RGCs. C57BL/6 mice were also treated with glial toxins, alpha-aminoadipic acid (AAA) or Neurostatin, along with KA. Reactive gliosis was assessed by immunostaining of retinal cross sections and retinal flat-mounts with glial fibrillary acidic protein (GFAP) and vimentin antibodies. Apoptotic cell death was assessed by TUNEL assays. Loss of RGCs was determined by immunostaining of flat-mounted retinas with Brn3a antibodies. Proteolytic activities of matrix metalloproteinase-9 (MMP-9), tissue plasminogen activator (tPA), and urokinase plasminogen activator (uPA) were assessed by zymography assays. GFAP-immunoreactivity indicated that KA induced reactive gliosis in both retinal astrocytes and in Muller cells. AAA alone or in combination with KA decreased GFAP and vimentin-immunoreactivity in Mϋller cells, but not in astrocytes. In addition AAA failed to decrease KA-mediated protease levels and apoptotic death of RGCs. In contrast, Neurostatin either alone or in combination with KA, decreased reactive gliosis in both astrocytes and Mϋller cells. Furthermore, Neurostatin decreased protease levels and prevented apoptotic death of RGCs. Our findings, for the first time, indicate that inhibition of reactive gliosis decreases protease levels in the retina, prevents apoptotic death of retinal neurons, and provides substantial neuroprotection.

Indexed as

2-Aminoadipic AcidAnimalsApoptosisGliosisGlycosphingolipidsImmunohistochemistryIn Situ Nick-End LabelingIn Vitro TechniquesKainic AcidMatrix Metalloproteinase 9MiceMice, Inbred BALB CRetinaRetinal Ganglion CellsTissue Plasminogen ActivatorUrokinase-Type Plasminogen Activator2-Aminoadipic AcidGlycosphingolipidsKainic AcidMatrix Metalloproteinase 9neurostatinTissue Plasminogen ActivatorUrokinase-Type Plasminogen Activator

Identifiers

PMID21483783
PMCPMC3069086
OpenAlexW1977437051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.